Prestige Consumer [PBH] vs United Therapeutics [UTHR] Detailed Stock Comparison
Prestige Consumer
NYSE
Loading...
United Therapeutics
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Prestige Consumer wins in 4 metrics, United Therapeutics wins in 15 metrics, with 0 ties. United Therapeutics appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Prestige Consumer | United Therapeutics | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 17.92 | 16.92 | United Therapeutics |
| Price-to-Book Ratio | 2.07 | 2.68 | Prestige Consumer |
| Debt-to-Equity Ratio | 56.91 | 0.00 | United Therapeutics |
| PEG Ratio | 16.12 | 1.77 | United Therapeutics |
| EV/EBITDA | 12.51 | 10.11 | United Therapeutics |
| Profit Margin (TTM) | 18.86% | 40.36% | United Therapeutics |
| Operating Margin (TTM) | 34.03% | 45.64% | United Therapeutics |
| EBITDA Margin (TTM) | 34.03% | 45.64% | United Therapeutics |
| Return on Equity | 12.30% | 19.30% | United Therapeutics |
| Return on Assets (TTM) | 6.50% | 12.96% | United Therapeutics |
| Free Cash Flow (TTM) | $243.29M | $1.08B | United Therapeutics |
| 1-Year Return | -8.70% | 24.59% | United Therapeutics |
| Price-to-Sales Ratio (TTM) | 3.33 | 6.37 | Prestige Consumer |
| Enterprise Value | $4.75B | $16.14B | United Therapeutics |
| EV/Revenue Ratio | 4.17 | 5.24 | Prestige Consumer |
| Gross Profit Margin (TTM) | 57.34% | 89.03% | United Therapeutics |
| Revenue per Share (TTM) | $23 | $69 | United Therapeutics |
| Earnings per Share (Diluted) | $4.29 | $25.12 | United Therapeutics |
| Beta (Stock Volatility) | 0.43 | 0.62 | Prestige Consumer |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Prestige Consumer vs United Therapeutics Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Prestige Consumer | -0.82% | 0.19% | -5.50% | -21.63% | -26.96% | -19.15% |
| United Therapeutics | 1.20% | 4.24% | 9.54% | 50.21% | 42.01% | 23.10% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Prestige Consumer | -8.70% | 26.31% | 69.11% | 30.16% | 500.76% | 421.49% |
| United Therapeutics | 24.59% | 114.46% | 326.34% | 258.80% | 694.13% | 1,312.23% |
News Based Sentiment: Prestige Consumer vs United Therapeutics
Prestige Consumer
News based Sentiment: MIXED
September presented a mixed bag for Prestige Consumer Healthcare, with disappointing revenue figures countered by positive EPS results and strategic moves like the Pillar5 Pharma acquisition. Analyst sentiment is divided, and the stock hit a 52-week low, creating a complex investment picture that requires careful monitoring.
United Therapeutics
News based Sentiment: MIXED
September was a pivotal month for United Therapeutics, marked by the highly positive TETON-2 trial results for Tyvaso in IPF, which drove significant stock gains and analyst upgrades. However, substantial insider selling and ongoing legal battles with Liquidia create a mixed investment picture, requiring careful monitoring of both the opportunities and risks.
Performance & Financial Health Analysis: Prestige Consumer vs United Therapeutics
| Metric | PBH | UTHR |
|---|---|---|
| Market Information | ||
| Market Cap | $3.79B | $19.33B |
| Market Cap Category | Mid cap | Large cap |
| 10 Day Avg. Volume | 406,280 | 924,001 |
| 90 Day Avg. Volume | 411,937 | 904,024 |
| Last Close | $62.84 | $443.44 |
| 52 Week Range | $61.28 - $90.04 | $266.98 - $444.57 |
| % from 52W High | -30.21% | -0.25% |
| All-Time High | $90.04 (Mar 10, 2025) | $444.57 (Oct 02, 2025) |
| % from All-Time High | -30.21% | -0.25% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.07% | 0.12% |
| Quarterly Earnings Growth | 0.01% | 0.11% |
| Financial Health | ||
| Profit Margin (TTM) | 0.19% | 0.40% |
| Operating Margin (TTM) | 0.34% | 0.46% |
| Return on Equity (TTM) | 0.12% | 0.19% |
| Debt to Equity (MRQ) | 56.91 | 0.00 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $37.06 | $158.65 |
| Cash per Share (MRQ) | $1.98 | $67.41 |
| Operating Cash Flow (TTM) | $251.52M | $1.37B |
| Levered Free Cash Flow (TTM) | $188.69M | $811.05M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | $0.00 | N/A |
Valuation & Enterprise Metrics Analysis: Prestige Consumer vs United Therapeutics
| Metric | PBH | UTHR |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 17.92 | 16.92 |
| Forward P/E | 16.12 | 15.25 |
| PEG Ratio | 16.12 | 1.77 |
| Price to Sales (TTM) | 3.33 | 6.37 |
| Price to Book (MRQ) | 2.07 | 2.68 |
| Market Capitalization | ||
| Market Capitalization | $3.79B | $19.33B |
| Enterprise Value | $4.75B | $16.14B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 4.17 | 5.24 |
| Enterprise to EBITDA | 12.51 | 10.11 |
| Risk & Other Metrics | ||
| Beta | 0.43 | 0.62 |
| Book Value per Share (MRQ) | $37.06 | $158.65 |
Financial Statements Comparison: Prestige Consumer vs United Therapeutics
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | PBH | UTHR |
|---|---|---|
| Revenue/Sales | $296.52M | $794.40M |
| Cost of Goods Sold | $126.51M | $92.50M |
| Gross Profit | $170.01M | $701.90M |
| Research & Development | N/A | $149.00M |
| Operating Income (EBIT) | $100.89M | $382.80M |
| EBITDA | $91.97M | $449.40M |
| Pre-Tax Income | $73.96M | $423.50M |
| Income Tax | $23.83M | $101.30M |
| Net Income (Profit) | $50.13M | $322.20M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | PBH | UTHR |
|---|---|---|
| Cash & Equivalents | $97.88M | $1.90B |
| Total Current Assets | $448.33M | $3.94B |
| Total Current Liabilities | $106.62M | $721.50M |
| Long-Term Debt | $1.04B | N/A |
| Total Shareholders Equity | $1.83B | $6.81B |
| Retained Earnings | $1.56B | $7.54B |
| Property, Plant & Equipment | $53.29M | $0 |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | PBH | UTHR |
|---|---|---|
| Operating Cash Flow | $47.51M | $463.80M |
| Capital Expenditures | $-3.48M | $-74.90M |
| Free Cash Flow | $58.37M | $386.30M |
| Debt Repayment | $-2.64M | $-100.00M |
| Common Stock Repurchase | $-11.31M | $0 |
Short Interest & Institutional Ownership Analysis
| Metric | PBH | UTHR |
|---|---|---|
| Shares Short | 1.51M | 2.78M |
| Short Ratio | 3.44 | 3.12 |
| Short % of Float | 0.04% | 0.08% |
| Average Daily Volume (10 Day) | 406,280 | 924,001 |
| Average Daily Volume (90 Day) | 411,937 | 904,024 |
| Shares Outstanding | 49.51M | 44.83M |
| Float Shares | 48.85M | 42.01M |
| % Held by Insiders | 0.01% | 0.02% |
| % Held by Institutions | 1.08% | 1.00% |
Dividend Analysis & Yield Comparison: Prestige Consumer vs United Therapeutics
| Metric | PBH | UTHR |
|---|---|---|
| Last 12-Month Dividend | $0.00 | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | $0.00 | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | $0.00 | N/A |
| Ex-Dividend Date | N/A | N/A |